Abstract
Background/Aim: We developed a scoring system to predict 1-year survival after radiosurgery for 1-3 brain metastases. This study aimed to validate this system. Patients and Methods: Seventy-six new patients were included in this validation study. Like in the original scoring-system, three factors (age, performance status, extra-cranial metastases) were used. For each factor, 1-year survival rates in % were divided by 10, and the three scoring-points were added for each patient. Results: Patient's scores were 10, 11, 13, 14, 16 or 17 points with 1-year survival rates ranging between 31% and 80%. Two groups, 10-14 and 16-17 points were formed. In the 14-16 points group, 1-year survival was 47% (versus 33% in the preceding study, p=0.060). In the 16-17 points group, 1-year survival rates were 75% versus 77% (p=0.79). Conclusion: In the more favorable group, the scoring-system was very reproducible. In the less favorable group, the difference was larger, but also not signficant.
Two randomized trials compared radiosurgery alone to radiosurgery combined with whole-brain radiotherapy (WBRT) for very few brain metastases. Both found that the addition of WBRT had a negative impact on neuro-cognitive function (1, 2). Therefore, omitting WBRT has become more popular. However, on the other hand, several studies showed that WBRT resulted in significantly better intracerebral control (1-4). And one has to be aware that progressive or new brain metastases have also be associated with neuro-cognitive decline (4, 5). Thus, patients with a high risk of developing new brain metastases or experience a progression or recurrence of the treated lesions may benefit from the addition of WBRT.
Furthermore, the increasing use of novel systemic treatments such as targeted therapies prior, during or after radiotherapy may lead to improved survival but may also damage brain tissue not affected by metastatic disease (5, 6). Thus, the treatment of a very limited number of brain metastases has become more complex recently and requires more personalized treatment regimens. Such a personalized treatment approach should always consider a patient's survival prognosis, which has been suggested for other metastatic situations (7-14). In order to facilitate the selection of the appropriate treatment regimen for a patient who is supposed receiving radiosurgery or fractionated stereotactic radiotherapy (FSRT) alone for a very limited number of brain metastases, a scoring-system that allows the physician to quickly estimate a patient's remaining survival time is helpful. We have developed such a scoring-system about three years ago (15). However, this system has not yet been validated. The present study was conducted to assess the validity and reproducibility of the previously developed scoring-system.
Patients and Methods
The data of 76 new patients treated with single-fraction radiosurgery alone (n=50) or FSRT alone (n=26) for 1 to 3 brain metastases from a solid tumor were retrospectively analyzed. The characteristics of these patients are summarized in Table I. Of this cohort, 41 patients were treated with a linear accelerator and 35 patients with a Cyberknife®. In case of single-fraction radiosurgery, doses ranged from 16 to 25 Gy. The most frequent dose was 20 Gy, which was administered in 33 of the 50 patients (66%), followed by 18 Gy, given in 13 patients (26%). In case of FSRT, 16 patients received 3 fractions of 7-11 Gy, 8 patients received 5 fractions of 5-8 Gy and 2 patients received 6 fractions of 5 Gy, respectively.
The present series served as a validation cohort for a scoring-system previously developed to predict the 1-year survival probability of patients receiving radiosurgery alone for 1 to 3 brain metastases (15). On the multivariate analysis of the previous study, three factors were found to be significantly associated with survival. These factors were age at the time of radiotherapy (≤60 versus ≥61 years), Eastern Cooperative Oncology Group (ECOG) performance score (0-1 versus 2) and extra-cranial metastases (no versus yes) (12). For each of these three factors, the 1-year survival rates in % were divided by 10, and subsequently, the three scoring-points were summed to generate the prognostic score for a specific patient. In the present validation study, the same procedure was used to obtain the prognostic score for each patient. The survival analyses were performed with the Kaplan-Meier method, and the Kaplan-Meier curves were compared with the Wilcoxon test (16). Significance was defined as a p-value of <0.05, a trend as a p-value of <0.10.
Results
The scores for individual patients were 10, 11, 13, 14, 16 or 17 points. These scores were associated with 1-year survival rates of 31%, 45%, 33%, 54%, 67% and 80%, respectively (p=0.009). Based on these data, two prognostic groups, i.e. 10-14 points and 16-17 points, were formed. The 1-year survival rates of these groups were 47% and 75%, respectively (p=0.099, Figure 1). The corresponding 1-year survival rates in the previous cohort used for developing the scoring-system were 33% (10-14 points) and 77% (16-17 points), respectively (p<0.001) (15). In addition, the survival data of the favorable groups (16-17 points) of the previous and the current study were compared. So were the survival data of the less favorable groups (10-14 points) in order to further investigate the reproducibility of the scoring-system. In the 14-16 points group, the 1-year survival rates were 47% in the current study versus 33% in the preceding study (p=0.060). In the 16-17 points group, the 1-year survival rates were 75% versus 77% (p=0.79).
Discussion
A considerable number of patients presenting with a very limited number of brain metastases are treated with radiosurgery or FSRT, which were shown to be more cost-effective than neurosurgery (17, 18). Radiosurgery either alone or combined with WBRT can lead to excellent long-term results (19). During recent years it has become increasingly popular to administer radiosurgery or FSRT alone rather than combining these approaches with WBRT. This was due to the results of two randomized trials (1, 2). One of these trials included 58 patients. Radiosurgery alone was associated with significantly less impairment of neuro-cognitive function than radiosurgery supplemented by WBRT at 4 months following treatment (24% versus 52%) (1). In the other trial, neuro-cognitive deficits at 3 months following treatment was observed in 64% and 92% of patients, respectively (p<0.001) (2). Another important finding from the first trial was that the 1-year intracerebral control rates were only 27% after radiosurgery alone compared to 73% after radiosurgery plus WBRT (p<0.001) (1). These results agree with those of a third randomized trial reporting 1-year intracerebral control rates of 24% and 53%, respectively (p<0.001) (4). However, improvement of intracerebral control did not translate into improved survival (1, 4). Therefore, many treating physicians feel that the omission of WBRT is justified in case of a very limited number (mainly 1-3 lesions) of brain metastases. WBRT appears to improve control in the brain but impairs quality of life and doesn't improve survival.
However, one may speculate that a considerable proportion of patients with 1-3 brain metastases might benefit from the addition of WBRT to radiosurgery or FSRT. In order to provide the appropriate treatment regimen for an individual patient, it would be important to be able to estimate the patient's risk of developing new brain metastases and the patient's remaining lifespan. Several scoring tools have already been reported that help judge the risk of developing new brain lesions (20-23). We have also developed a scoring-system particularly for patients treated with radiosurgery alone for 1-3 brain metastases that enabled the treating physicians to estimate a patient's 1-year survival probability (15). This system was based on three factors significantly associated with survival, namely age, performance score and extra-cranial spread. It was the first scoring-system for patients receiving linear-accelerator based radiosurgery alone. Scoring points ranged from 10 to 17, and two survival groups were created with 1-year survival rates of 33% (10-14 points) and 77% (16-17 points), respectively (15). However, the scoring-system has not yet been validated. Therefore, the present study was performed including 76 new patients treated with radiosurgery or FSRT alone for 1-3 brain metastases. In this study, the 1-year survival rates were 47% and 75%, respectively. The intergroup comparisons between both studies revealed that the findings in the 16-17 points group were very similar and could, therefore, be considered valid and well reproducible. In the 10-14 points group, the 1-year survival rate in the present study was 14% higher than in the previous study. This finding may be a consequence of improved systemic treatments (6). However, the difference regarding the 1-year survival rate between the two prognostic groups in the current study still showed a trend and would likely be significant if the number of patients (n=76) was as high as in the previous study (n=214). Therefore, the scoring-system may be considered valid to a certain extent also in the 10-14 points group. However, it becomes obvious that due to improvement of anticancer treatments, survival scores need to be updated in appropriately large patient cohorts from time to time.
Characteristics of the validation cohort (n=76).
In the 16-17 points group, 75% of the deaths were due to new brain metastases outside the irradiated areas and not to extra-cranial spread. Therefore, the addition of WBRT to radiosurgery or FSRT should be considered. Systemic treatment may be postponed until extra-cranial spread occurs. In contrast, in the 10-14 points group 50% of deaths were due to extra-cranial metastases and systemic treatment should be strongly considered and administered early. When following these suggestions, the retrospective nature of both studies must be considered.
In conclusion, in the more favorable group (16-17 points), the scoring-system proved to be valid and well reproducible. In the less favorable group, the 1-year survival was non-significantly better than in the previous study, which was most likely due to improved systemic treatments including modern targeted therapies. Thus, the scoring-system can be used to estimate the 1-year survival probability of patients assigned to radiosurgery or FSRT alone for 1-3 brain metastases.
Comparison of the two prognostic groups (10-14 versus 16-17 points) for survival.
Footnotes
This article is freely accessible online.
Conflicts of Interest
On behalf of all Authors, the corresponding Author states that there is no conflict of interest related to this study.
- Received November 28, 2017.
- Revision received December 10, 2017.
- Accepted December 11, 2017.
- Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
References
In this issue
Jump to section
Related Articles
Cited By...
- Pre-Treatment Seizures in Patients With 1-3 Cerebral Metastases Receiving Local Therapies Plus Whole-brain Radiotherapy
- Predicting the Risk of Subsequent Distant Brain Metastases After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients
- Survival After Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT) for Cerebral Metastases in the Elderly
- Occurrence of Seizures Prior to Single-fraction Radiosurgery or Multi-fraction Stereotactic Radiotherapy in Patients With Very Few Brain Metastases
- Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer
- Confirmatory Analysis of QUARTZ Study Results: Survival Prolongation After Whole-brain Radiotherapy
- Estimating Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Whole-brain Radiotherapy With a New Tool
- Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses
- Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM
- Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement
- Patterns of Treatment and Outcome in Patients With 20 or More Brain Metastases
- Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate Cancer